News | May 23, 2026
Gujarat Themis Biosyn acquires MicroBiopharm Japan for Rs. 1,300 Cr
Transition to a fermentation-based globally integrated CDMO platform
Transition to a fermentation-based globally integrated CDMO platform
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
